Guangji Pharm. Achieves Operating Revenue of 738 Million Yuan and 56.27% Surge Y/Y for 2023 & Q1 2024 Respectively; The VB12 Line in its Holding Subsidiary Guangji Pharmaceutical (Mengzhou) Co., Ltd. Halts Production